e-Edition
Obituaries
Special Sections
Special Occasions
Contact

Subscribe
Paywall Login
Login to Comment
Register

December 11th, 2017

jobs

homes

Home
News
Sports
Business
Entertainment
Classifieds
Commentary

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

51.57 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Dec 31, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2

...

24 25 26 27 28 29 30 31 32

...

34 35 Next >

The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More ↗

November 08, 2021

Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out...

Via Benzinga

The Old Lady Of Threadneedle Street ↗

November 05, 2021

US markets are up on better jobs growth reported for October today.

Via Talk Markets

Will Pfizer Outgun Merck With Oral COVID-19 Pill? ↗

November 05, 2021

Merck, Inc. (NYSE: MRK) is locking horns with peer Pfizer, Inc. (NYSE: PFE) in what could be termed as the battle supremacy in the COVID-19 treatment market. The stakes are high,...

Via Benzinga

Thursday Market Overview ↗

November 04, 2021

If you are an IBM shareholder you now own something new Kyndryl.

Via Talk Markets

7 European Stocks to Buy to Diversify Your Portfolio ↗

November 04, 2021

While exposure to U.S.-based securities continues to be a good idea, you can diversify your opportunities by considering European stocks.

Via InvestorPlace

Novartis To Offload Its Stake Back To Roche For $20.7B ↗

November 04, 2021

Novartis AG (NYSE: NVS), a shareholder in Roche Holdings AG (OTC: RHHBY) for more than 20 years, would sell its entire stake, which is nearly one-third voting...

Via Benzinga

Galecto To Test GB1211 Combined with Roche's Tecentriq In First Line Lung Cancer Setting ↗

November 02, 2021

Galecto Inc (NASDAQ: GLTO) has entered into a clinical trial supply agreement with Roche Holdings AG (OTC: RHHBY) to explore the combination of GB1211 in...

Via Benzinga

Cyber Currency ↗

October 26, 2021

Canadian stocks are particularly buoyant and not just in energy which is a riser today because the loony is up against the buck.

Via Talk Markets

Default Avoided ↗

October 22, 2021

The Chinese real estate firm Evergrande managed to pay the interest it owes to foreign bondholders.

Via Talk Markets

Why Atea Pharmaceuticals Stock Got Crushed This Week ↗

October 22, 2021

A mid-stage trial miss caused investors to hit the exits this week.

Via The Motley Fool

FDA Approves Genentech’s Susvimo, a First-of-Its-Kind Therapeutic Approach for Wet Age-Related Macular Degeneration (AMD)

October 22, 2021

From Genentech

Via Business Wire

The Daily Biotech Pulse: Athira CEO Resigns Over Doctored Research, Merck's Keytruda Snags First Approval For Breast Cancer In Europe, Minerva And Xilio IPOs ↗

October 22, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Athira Names Chief Operating Officer Mark Litton As Next CEO as Leen Kawas...

Via Benzinga

Why Cortexyme Thinks It Could Be Next In The Mega Alzheimer's Drug Market ↗

October 21, 2021

Cortexyme is testing a twice-day pill to treat Alzheimer's disease.

Via Investor's Business Daily

Wednesday Market Coverage ↗

October 20, 2021

Today gold rose again despite the active market for bitcoin and the lower Chinese demand for mine products like iron and coal.

Via Talk Markets

Roche Expects Higher FY21 Sales As Delta Variant Boosts Demand For Diagnostics ↗

October 20, 2021

Roche Holding AG (OTC: RHHBY) raised its 2021 sales forecast after posting an 8% rise in nine-month revenues, driven by demand for COVID-19 tests and the strong...

Via Benzinga

AstraZeneca Pulls Plug On MCL-1 Cancer Drug Trial ↗

October 20, 2021

AstraZeneca Plc (NASDAQ: AZN) has paused an active Phase 1 trial of AZD5991, a direct inhibitor of MCL-1, citing a potential safety issue. Two years ago, the FDA hit ...

Via Benzinga

The Daily Biotech Pulse: Novavax Retreats Amid Vaccine Issues, LumiraDx COVID Test Approved In India, Sesen Shines On Positive Bladder Cancer Review ↗

October 20, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Novavax Shares React to Reports Of Manufacturing Issues With Its COVID-19...

Via Benzinga

Bitcoin Futures Arrive ↗

October 19, 2021

Today you can finally hold Bitcoins via an exchange-traded fund.

Via Talk Markets

Why Atea Pharmaceuticals Is Imploding Today ↗

October 19, 2021

The company's oral COVID-19 treatment looks like a dud in the mild-to-moderate COVID-19 setting.

Via The Motley Fool

Atea Pharma Stock Crashes After Merck-Rivaling Covid Pill Lags In Midstage Test ↗

October 19, 2021

Atea Pharmaceuticals said its Covid pill didn't lower viral loads in all patients.

Via Investor's Business Daily

David v Goliath in The Race to Develop an Oral Therapy for COVID-19 ↗

October 19, 2021

Photo by Towfiqu barbhuiya on Unsplash Broad agreement in the world of science can be a rarity. However, one thing that public health leaders active in the fight against COVID-19...

Via Benzinga

The Daily Biotech Pulse: Entasis, Dermata Spike Higher On Positive Readouts, J&J Q3 EPS Beats Estimates, Wave Life Sciences Regains Right To CNS Portfolio ↗

October 19, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Entasis Announces Positive Data For Late-Stage Study Of SUL-DUR In...

Via Benzinga

Why Are Atea Pharmaceuticals Shares Plunging Today? ↗

October 19, 2021

Atea Pharmaceuticals Inc (NASDAQ: AVIR) has reported data from the Phase 2 MOONSONG trial of AT-527 in the outpatient setting in patients with mild or moderate...

Via Benzinga

Chinese Growth Level ↗

October 18, 2021

The hot news today was a much weaker Chinese growth level this year, of 4.9% because of supply chain issues.

Via Talk Markets

Vaccine Makers Slump As Oral Antivirals Begin To Take Center Stage ↗

October 18, 2021

Vaccine makers have been under tremendous selling pressure over the past 2 months driven by policy, the rising delta wave, and breakthrough infections. This slump has been a boost for the oral...

Via Talk Markets

Ionis Stock Collapses On Another 'Misstep' As Biogen-Partnered ALS Drug Flops ↗

October 18, 2021

Biogen and Ionis' approach to Lou Gehrig's disease missed its key goal.

Via Investor's Business Daily

Roche's Tecentriq Wins FDA Approval In Adjuvant Lung Cancer Setting ↗

October 18, 2021

The FDA has greenlit Roche Holdings AG's (OTC: RHHBY) Tecentriq and platinum-based chemotherapy as post-surgery treatment for non-small cell lung cancer with...

Via Benzinga

The Week Ahead In Biotech (Oct. 18-23): J&J, Biogen Kickstart Big Pharma Earnings, Regeneron-Sanofi, Roche Await FDA Decisions And IPOs ↗

October 18, 2021

Biotech stocks rebounded in the week ended Oct. 15, bouncing from third straight weekly losses. The strength came amid a broader market rally and some sector-specific news....

Via Benzinga

Crispr: A Fallen Angel In Gene Editing ↗

October 16, 2021

As with most promising biotech companies, investors bid their prices up for CRSP based on its potential for early profits. When the payoff didn't occur on schedule, investors bailed out. Once it...

Via Talk Markets

Europe's Unicorns ↗

October 15, 2021

After markets jumped yesterday, we saw a lot of bounce today although gold fell back a bit.

Via Talk Markets

< Previous 1 2

...

24 25 26 27 28 29 30 31 32

...

34 35 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

More ways to get to us

Facebook

Twitter

YouTube

ePaper Login
Subscribe
Subscription Services
Archive

About Us

The Lethbridge Herald
Other Publications
Food For Thought

Contact
Careers

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

Advertising
Terms and Conditions & Privacy Policy